The efficacy of pindolol in reducing weight gain associated with the use of Olanzapine

ISRCTN ISRCTN87255415
DOI https://doi.org/10.1186/ISRCTN87255415
Secondary identifying numbers N0530115316
Submission date
12/09/2003
Registration date
12/09/2003
Last edited
06/12/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Craig Ritchie
Scientific

Metabolic and Clinical Trials Unit
Royal Free and University College Medical School
Royal Free Campus
Rowland Hill Street
London
NW3 2PF
United Kingdom

Phone +44 020 7794 0500 x3951

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific title
Study objectivesThe aim of the study is to determine the effect that the addition of pindolol has on weight gain associated with Olanzapine. We hypothesise that due to its central effects on serotonergic pathways, pindolol will increase feelings of satiety and consequently reduce weight gain commonly observed in the treatment of psychosis with Olanzapine.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedObesity
InterventionRandomised controlled trial:
A. Olanzapine treatment in combination with pinadolol
B. Olazapine treatment alone
Intervention typeOther
Primary outcome measureOlanzapine is commonly used in the treatment of schizophrenia. Whilst generally well tolerated, weight gain is known to effect compliance and acceptability to many patients. In patients who continue to take Olanzapine despite gaining weight there are general health and psychological ramifications. If weight gain could be minimised then this burden may be reduced, leading to a lessening of pressure upon NHS resources.
Secondary outcome measuresNot provided at time of registration
Overall study start date01/08/2002
Completion date01/09/2003

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants36
Key inclusion criteria36 Participants, who will be recruited through the clinicians working with Camden and Islington Mental Health and Social Care Trust.
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/08/2002
Date of final enrolment01/09/2003

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Metabolic and Clinical Trials Unit
London
NW3 2PF
United Kingdom

Sponsor information

Department of Health (UK)
Government

Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom

Website http://www.doh.gov.uk

Funders

Funder type

Government

North Central London Community Research Consortium

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan